We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed at $220.81 in the latest trading session, marking a +2.1% move from the prior day. This move outpaced the S&P 500's daily loss of 0.1%. At the same time, the Dow added 0.57%, and the tech-heavy Nasdaq lost 0.33%.
Coming into today, shares of the drugmaker had gained 4.88% in the past month. In that same time, the Medical sector gained 0.86%, while the S&P 500 gained 2.57%.
Market participants will be closely following the financial results of AbbVie in its upcoming release. The company is expected to report EPS of $3.26, up 8.67% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $15.54 billion, showing a 7.5% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of $12.02 per share and a revenue of $60.64 billion, demonstrating changes of +18.77% and +7.64%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for AbbVie. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.14% decrease. Right now, AbbVie possesses a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 18. This signifies a premium in comparison to the average Forward P/E of 14.13 for its industry.
One should further note that ABBV currently holds a PEG ratio of 1.39. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.56.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 52, putting it in the top 22% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note
AbbVie (ABBV - Free Report) closed at $220.81 in the latest trading session, marking a +2.1% move from the prior day. This move outpaced the S&P 500's daily loss of 0.1%. At the same time, the Dow added 0.57%, and the tech-heavy Nasdaq lost 0.33%.
Coming into today, shares of the drugmaker had gained 4.88% in the past month. In that same time, the Medical sector gained 0.86%, while the S&P 500 gained 2.57%.
Market participants will be closely following the financial results of AbbVie in its upcoming release. The company is expected to report EPS of $3.26, up 8.67% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $15.54 billion, showing a 7.5% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of $12.02 per share and a revenue of $60.64 billion, demonstrating changes of +18.77% and +7.64%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for AbbVie. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.14% decrease. Right now, AbbVie possesses a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 18. This signifies a premium in comparison to the average Forward P/E of 14.13 for its industry.
One should further note that ABBV currently holds a PEG ratio of 1.39. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.56.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 52, putting it in the top 22% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.